Analytical Data
-
基因名
DMD
- Application
-
别名
DMD；Dystrophin
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P11532
-
表达区间
3076-3674aa
-
氨基酸序列
MREQLKGHETQTTCWDHPKMTELYQSLADLNNVRFSAYRTAMKLRRLQKA LCLDLLSLSAACDALDQHNLKQNDQPMDILQIINCLTTIYDRLEQEHNNL VNVPLCVDMCLNWLLNVYDTGRTGRIRVLSFKTGIISLCKAHLEDKYRYL FKQVASSTGFCDQRRLGLLLHDSIQIPRQLGEVASFGGSNIEPSVRSCFQ FANNKPEIEAALFLDWMRLEPQSMVWLPVLHRVAAAETAKHQAKCNICKE CPIIGFRYRSLKHFNYDICQSCFFSGRVAKGHKMHYPMVEYCTPTTSGED VRDFAKVLKNKFRTKRYFAKHPRMGYLPVQTVLEGDNMETPVTLINFWPV DSAPASSPQLSHDDTHSRIEHYASRLAEMENSNGSYLNDSISPNESIDDE HLLIQHYCQSLNQDSPLSQPRSPAQILISLESEERGELERILADLEEENR NLQAEYDRLKQQHEHKGLSPLPSPPEMMPTSPQSPRDAELIAEAKLLRQH KGRLEARMQILEDHNKQLESQLHRLRQLLEQPQAEAKVNGTTVSSPSTSL QRSDSSQPMLLRVVGSQTSDSMGEEDLLSPPQDTSTGLEEVMEQLNNSFP SSRGHNVGSLFHMADDLGRAMESLVSVMTDEEGAE
-
分子量
96 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Duchenne muscular dystrophy (DMD) is a severe genetic disorder characterized by progressive skeletal muscle degeneration due to mutations in the dystrophin gene. The absence of dystrophin, a crucial protein that stabilizes muscle cell membranes, leads to muscle fiber damage, inflammation, and ultimately, loss of muscle function. As DMD primarily affects boys and manifests in early childhood, it results in significant morbidity and mortality, with affected individuals often requiring wheelchair assistance by their teenage years. Given the urgent need for effective therapies, researchers have explored various strategies to restore dystrophin expression or function. One promising approach involves the use of recombinant dystrophin proteins or protein substitutes, which aim to partially or fully restore the dystrophin complex at the muscle membrane. These DMD recombinant proteins can potentially ameliorate muscle damage and improve muscle function by integrating into the cellular architecture and providing mechanical stability to the muscle fibers. Recent advancements in gene editing technologies, such as CRISPR-Cas9, and innovative delivery systems, including adeno-associated viral vectors, have further accelerated the development of these recombinant proteins, paving the way for novel therapeutic avenues. The ongoing research in DMD recombinant proteins not only holds promise for treating affected individuals but also enhances our understanding of muscle biology and the dystrophin-associated glycoprotein complex, which could have wider implications for addressing other muscular dystrophies and related disorders.
